ORMP Earnings Date: Nov 12, 2026 (Estimated) — Oramed Pharmaceuticals Inc.
NASDAQ
Updated
When is ORMP's next earnings date?
Oramed Pharmaceuticals Inc. (ORMP) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.43.
How did ORMP do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Oramed Pharmaceuticals Inc. posted EPS of $1.84 versus the $0.43 estimate, a beat of 327.9%. Revenue was $0. The stock's 1-day post-earnings move was +1.2%.
How much does ORMP stock move after earnings?
ORMP beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.5% (up or down) in the day after earnings.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | 0.43 | 1.84 | +327.91% | $0 | ✅ Beat | +1.19% | +8.81% | +13.81% |
| 2026-05-19 | Q1 2026 | -0.08 | 0.91 | +1237.50% | $0 | ✅ Beat | -1.15% | -8.08% | -10.39% |
| 2026-03-25 | Q4 2025 | -0.03 | 0.24 | +900.00% | $0 | ✅ Beat | -5.14% | -3.14% | +10.00% |
| 2025-11-13 | Q3 2025 | -0.08 | 1.26 | +1675.00% | $2.0M | ✅ Beat | -2.91% | +0.85% | +28.34% |
| 2025-03-27 | Q4 2024 | -0.07 | -0.26 | -271.43% | $0 | ❌ Miss | -3.92% | -6.06% | -2.61% |
| 2024-11-07 | Q3 2024 | -0.07 | -0.48 | -585.71% | $0 | ❌ Miss | -2.97% | -1.89% | +5.86% |
| 2024-03-06 | Q4 2023 | -0.12 | 0.33 | +375.00% | $0 | ✅ Beat | -0.37% | -3.51% | -9.08% |
| 2023-08-10 | Q2 2023 | -0.11 | -0.03 | +72.73% | $674,000 | ✅ Beat | +2.49% | -1.24% | -4.71% |
Showing last 8 quarters.